港股异动 | 心通医疗-B(02160)再涨超5% 微创医疗拟将CRM业务注入心通医疗有助建立心脏病产品平台

智通财经2025-07-21

智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨4.2%，报1.24港元，成交额1100.82万港元。消息面上，微创医疗(00853)此前宣布，正考虑一项关于其CRM业务的策略性重组建议，可能将其微创心律(CRM业务)与微创心通的结构性心脏病业务合并。两项业务合并后，将形成一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的TAVI、LAA等全面的产品组合。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2553440918?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-21 10:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553440918","market":"us","top_or_hot":-1,"title":"港股异动 | 心通医疗-B(02160)再涨超5% 微创医疗拟将CRM业务注入心通医疗 有助建立心脏病产品平台","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨4.2%，报1.24港元，成交额1100.82万港元。消息面上，微创医疗(00853)此前宣布，正考虑一项关于其CRM业务的策略性重组建议，可能将其微创心律(CRM业务)与微创心通的结构性心脏病业务合并。两项业务合并后，将形成一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的TAVI、LAA等全面的产品组合。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1319899.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 心通医疗-B(02160)再涨超5% 微创医疗拟将CRM业务注入心通医疗 有助建立心脏病产品平台</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 心通医疗-B(02160)再涨超5% 微创医疗拟将CRM业务注入心通医疗 有助建立心脏病产品平台\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-21 10:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1319899.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨4.2%，报1.24港元，成交额1100.82万港元。消息面上，微创医疗(00853)此前宣布，正考虑一项关于其CRM业务的策略性重组建议，可能将其微创心律(CRM业务)与微创心通的结构性心脏病业务合并。两项业务合并后，将形成一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的TAVI、LAA等全面的产品组合。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1319899.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0689626769.HKD","symbol_name":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1319899.html","article_id":"2553440918","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553440918","pubTimestamp":1753065462,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，心通医疗-B再涨超5%，截至发稿，涨4.2%，报1.24港元，成交额1100.82万港元。消息面上，微创医疗此前宣布，正考虑一项关于其CRM业务的策略性重组建议，可能将其微创心律与微创心通的结构性心脏病业务合并。两项业务合并后，将形成一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的TAVI、LAA等全面的产品组合。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","BK4607":"DeepSeek概念股","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU1046421795.USD":"富达环球科技A-ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4581":"高盛持仓","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","BK4543":"AI","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","BK4534":"瑞士信贷持仓","LU0082616367.USD":"摩根大通美国科技A（dist）","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","02160":"微创心通-B","LU0557290698.USD":"施罗德环球可持续增长基金","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","CRM":"赛富时","BK4535":"淡马锡持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","00853":"微创医疗","LU0109392836.USD":"富兰克林科技股A","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4579":"人工智能","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","BK4548":"巴美列捷福持仓","BK1585":"昨日强势股"},"translate_title":"Changes in Hong Kong stocks | Xintong Medical-B (02160) rose more than 5% Minimally Invasive Medical plans to inject CRM business into Xintong Medical to help establish a heart disease product platform","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRM":1,"02160":1,"00853":1},"content_text":"智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨4.2%，报1.24港元，成交额1100.82万港元。消息面上，微创医疗(00853)此前宣布，正考虑一项关于其CRM业务的策略性重组建议，可能将其微创心律(CRM业务)与微创心通的结构性心脏病业务合并。两项业务合并后，将形成一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的TAVI、LAA等全面的产品组合。值得注意的是，2021年7月，微创医疗为微创心律引入高瓴投资等机构，但约定若微创心律未能在2025年7月17日前上市，且上市后的市值未达到15亿美元、募资少于1.5亿美元，则高瓴投资等机构有权要求微创心律赎回股份。分析人士指出，微创医疗当前是在试图借微创系自身的壳，来降低曾经的对赌赎回风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553440918","isCrawlerRequest":true}

港股异动 | 心通医疗-B(02160)再涨超5% 微创医疗拟将CRM业务注入心通医疗 有助建立心脏病产品平台

精彩评论

港股异动 | 心通医疗-B(02160)再涨超5% 微创医疗拟将CRM业务注入心通医疗有助建立心脏病产品平台